Intervacc
Intervacc AB is a Swedish animal health biotech developing recombinant fusion protein vaccines, led by its flagship equine strangles vaccine Strangvac® (approved in 16+ European markets) and the pipeline-stage Piggivac® pig vaccine. It serves equine veterinarians and owners across Europe via direct sales (Nordvacc) and Dechra distribution, and is pursuing US regulatory entry.
- Company typePublic
- Founded2014
- HeadquartersHägersten, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Intervacc does
Intervacc AB (publ) is a Swedish biotechnology company listed on Nasdaq First North Growth Market (ticker: IVACC) that develops vaccines based on recombinant fusion protein technology for animal health applications. The company's core technology platform originated from research at Karolinska Institutet and the Swedish University of Agricultural Sciences (SLU), generating broad immune responses by targeting multiple virulence pathways of complex bacterial pathogens. Its flagship commercial product, Strangvac®, is a recombinant subunit vaccine against equine strangles (Streptococcus equi) approved in the EU, UK, Iceland, Norway, and Liechtenstein, providing over 90% protection following booster dose and uniquely offering DIVA (Differentiating Infected from Vaccinated Animals) capability that enables continued disease surveillance. The pipeline includes Piggivac® (INV274), a pig vaccine against Streptococcus suis that became the first globally to demonstrate statistically significant protection against serotypes ST1 and ST16 via maternal immunity, and INV412, a mastitis vaccine candidate for dairy cattle.
The company operates a hybrid distribution model: direct sales through its wholly-owned Nordvacc Läkemedel subsidiary (which has sold more than 200 million vaccine doses and holds distribution rights to 25 products across 8 Scandinavian and Baltic countries) for Scandinavia, and an exclusive distribution agreement with Dechra Pharmaceuticals PLC covering the rest of Europe (extended through April 2028). 2025 net sales were SEK 20.087 million, up 70% year-over-year, and the company is pursuing US regulatory approval with clinical safety studies initiated in December 2025. Beyond Strangvac and Piggivac, Intervacc operates Mybac-Vettech Laboratoriet for clinical microbiological analyses and is funded through a mix of equity (including a SEK 193 million rights issue in February 2025 that brought HealthCap IX Investments AB as a ~26% shareholder), EU grants (Eurostars-2/3), and Swedish innovation agency (Vinnova) grants.
Revenue is generated primarily from vaccine product sales (one-time purchase model through veterinary channels), with strategic positioning that emphasizes antimicrobial resistance reduction, scientific engagement via Key Opinion Leader networks, and awareness campaigns such as Strangles Awareness Week. The company is led by CEO Carl-Johan Dalsgaard (appointed February 2026, previously AstraZeneca) with Andrew Waller as CSO, Jan Persson as CFO, and Anna-Carin Lagerlöf as Director of Sales & Marketing, supported by Board Chair Emil Billbäck (appointed May 2026).
Intervacc firmographics
Firmographics- Name
- Intervacc
- Legal name
- Intervacc AB (publ)
- Website
- https://intervacc.se
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Intervacc AB is a Swedish animal health biotech developing recombinant fusion protein vaccines, led by its flagship equine strangles vaccine Strangvac® (approved in 16+ European markets) and the pipeline-stage Piggivac® pig vaccine. It serves equine veterinarians and owners across Europe via direct sales (Nordvacc) and Dechra distribution, and is pursuing US regulatory entry.
- Ownership category
- akta.pro rank
Intervacc industry classification
Industry- Product category
- Animal Health Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Veterinary Vaccines (Biologics) (HLAMAEAL)
- akta.pro secondary industries
- Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Intervacc is headquartered
LocationHeadquarters
- HQ city
- Hägersten
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Intervacc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Vaccine Product Sales: Revenue generated from sales of Strangvac vaccine for horses, sold directly in Scandinavia and through distribution partner Dechra across Europe. Net sales of SEK 20,087 thousand in 2025, up 70% from SEK 11,787 thousand in 2024.
- Distribution Rights and Sales: Nordvacc subsidiary sells vaccines and pharmaceuticals across Scandinavia and Baltic countries with distribution rights to 25 products in 8 countries.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Intervacc product offering
Product offeringCore offering
Intervacc develops and commercializes vaccines based on recombinant fusion proteins for animal health, with flagship product Strangvac® protecting horses against strangles (Streptococcus equi) and pipeline product Piggivac® targeting Streptococcus suis in pigs. The company sells Strangvac directly in Scandinavia and through Dechra Pharmaceuticals across Europe, while expanding its vaccine pipeline to address mastitis in dairy cattle.
Product overview
Intervacc is a Swedish animal health group developing vaccines based on recombinant protein fusion technology for animals. The company's core product portfolio includes Strangvac®, an approved equine strangles vaccine registered in 16 European markets; Piggivac®, a pig vaccine against Streptococcus suis in advanced development; and two additional vaccine candidates (INV274 and INV412). Through subsidiaries Nordvacc Läkemedel (sales/distribution) and Mybac-Vettech Laboratoriet (analyses), Intervacc combines in-house vaccine development with established commercial infrastructure across European markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Strangvac® A recombinant fusion protein vaccine against equine strangles (caused by Streptococcus equi), approved for sale and marketing in the EU, UK, Iceland, Norway, and Liechtenstein. Administered intramuscularly, it provides over 90% protection following booster dose and is the only strangles vaccine that permits diagnosis of exposed or infected horses.
- Piggivac® A subunit vaccine against Streptococcus suis infections in pigs, based on Intervacc's recombinant fusion protein platform. Administered to pregnant sows intramuscularly, transferring maternal immunity to piglets. Demonstrated statistically significant protection against virulent serotypes ST1 (serotype 2) and ST16 (serotype 9). No approved S. suis vaccines currently exist for pigs.
- Nordvacc Läkemedel (Distribution Services) A wholly-owned subsidiary of Intervacc operating as a sales and distribution organization with over 30 years of experience, having sold more than 200 million vaccine doses on the European animal health market. Handles distribution of Intervacc's products in Scandinavia and holds distribution rights to multiple products across 8 countries.
- Mybac-Vettech Laboratoriet (Microbiological Analyses) A subsidiary of Nordvacc performing clinical microbiological analyses, supporting diagnostic and analytical service capabilities.
Quantifiable outcome
- Over 90% protection following booster vaccination against strangles
- +3 more outcomes
Companies that use Intervacc
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Intervacc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Intervacc partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Moredun ScientificcoreContract research organization specializing in animal health in Edinburgh, UK. Collaborating on Streptococcus suis vaccine (INV274/Piggivac) development including challenge studies and pivotal registration studies. Project co-funded by Eurostars 3 program.
- Dechra Pharmaceuticals PLCcoreFive-year distribution agreement (original April 2021, extended by 2 years from April 2026) for Strangvac vaccine in Europe excluding Scandinavia, Iceland, and Baltic countries. Dechra has launched Strangvac in 14 countries including UK, France, Germany, Spain, Portugal, Ireland, Poland, Slovenia, and Italy.
- Testa CentercoreCollaboration with Testa Center in Uppsala, Sweden for scale-up manufacturing of Streptococcus suis vaccine component. Project involves optimizing biopharmaceutical production processes with Vinnova funding of 800,000 SEK.
- Swedish University of Agricultural Sciences (SLU)coreMulti-year contract for development of innovative animal health vaccines using recombinant proteins. Research collaboration provides foundation for Intervacc's vaccine platform technology.
- 3P BiopharmaceuticalscoreManufacturing partner in Pamplona, Spain for large-scale commercial production of drug substances in Strangvac vaccine. Technology transfer and validation batch production completed for registration.
- Praxis Pharmaceuticals (LIOF-Pharma)coreProvider of final formulation, vial filling, packaging, and final release of finished Strangvac product in Spain.
- Nordvacc Läkemedel ABcoreWholly-owned subsidiary acquired in 2014 providing established distribution network in Scandinavia and Baltic countries. Has sold more than 150 million vaccine doses and holds distribution rights to 25 products in 8 countries. Also owns Mybac-Vettech performing clinical microbiological analyses.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Intervacc competitors and assessment
Company assessmentBroad incumbents
- Virbac: Independent French animal health company with a strong vaccine portfolio across livestock, equine, and companion animals, plus a meaningful direct-sales presence in Europe. Closely comparable as a mid-sized independent animal vaccine specialist with European roots and international ambitions.
- Vetoquinol: Independent French animal health company with a strong veterinary biologics and pharmaceutical portfolio, including equine and livestock products. Comparable as a mid-sized European independent animal health specialist with similar geographic and end-market overlap to Intervacc.
- Ceva Santé Animale: Major independent global animal health player headquartered in France, especially strong in poultry and swine vaccines. Relevant peer for the swine (Piggivac/INV274) side of Intervacc's portfolio and as a benchmark for independent vaccine R&D organizations competing against Big Pharma incumbents.
- Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company (acquired by EQT in 2025) with strong European and North American equine/small animal footprint. Dechra is Intervacc's distribution partner for Strangvac in Europe and is directly comparable as a specialty vet pharma commercial channel.
- Phibro Animal Health: Animal health and nutrition company with a meaningful vaccine and anti-infective business serving livestock and poultry. Comparable as a public pure-play animal health company whose stock-based valuation benchmark is helpful in sizing Intervacc's potential enterprise value trajectory.
- Merck Animal Health (MSD Animal Health): The animal health division of Merck/MSD, offering vaccines, anti-infectives, and parasiticides globally. Operates the broadest portfolio of licensed veterinary biological products across species and is a key competitor and benchmark for any animal vaccine developer targeting livestock or equine markets.
- Zoetis: World's largest pure-play animal health company, offering a broad portfolio of vaccines, parasiticides, and diagnostics across livestock and companion animals. Comparable as a manufacturer of veterinary biologics, including equine and livestock vaccines, with established global commercial scale that dwarfs Intervacc's current footprint.
- Elanco Animal Health: Global pure-play animal health company with significant vaccine franchises in livestock and companion animals (acquired Bayer Animal Health in 2020). A broad incumbent comparable to Intervacc's commercial ambition across species, though at much larger scale.
- Boehringer Ingelheim Animal Health: One of the largest veterinary biologics manufacturers in the world after the Merial acquisition. Develops and markets vaccines for swine, cattle, equine, and companion animals, making it a directly comparable vaccine R&D and commercial platform to Intervacc's pipeline.
Emerging players
- IDT Biologika: German veterinary biologics contract manufacturer and vaccine developer with strong expertise in bacterial vaccines across species. Comparable as a specialized European veterinary biologics platform — relevant for both competitive technology benchmarking and as a potential manufacturing counterpart for Intervacc-type recombinant subunit products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Intervacc social profiles
Digital presenceIntervacc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intervacc leadership team
Management profileNumber of profiles
Profiles7 records
Intervacc subsidiaries and ownership
Company hierarchySubsidiaries2 records
Intervacc funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intervacc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intervacc
What does Intervacc do?
Intervacc develops and commercializes vaccines based on recombinant fusion proteins for animal health, with flagship product Strangvac® protecting horses against strangles (Streptococcus equi) and pipeline product Piggivac® targeting Streptococcus suis in pigs. The company sells Strangvac directly in Scandinavia and through Dechra Pharmaceuticals across Europe, while expanding its vaccine pipeline to address mastitis in dairy cattle.
Is Intervacc a public or private company?
Intervacc is a public company. It is classified as public and is currently operating.
When was Intervacc founded?
Intervacc was founded in 2014. It employs 11 to 50 people.
Where is Intervacc based?
Intervacc is headquartered in Hägersten, Sweden, in the Europe region.
How does Intervacc make money?
Two revenue lines are on record. Vaccine Product Sales are the primary driver. The others are distribution Rights and Sales.
Who are Intervacc's main competitors?
Broad incumbents on record are Virbac, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, Phibro Animal Health, Merck Animal Health (MSD Animal Health), Zoetis, Elanco Animal Health and Boehringer Ingelheim Animal Health. IDT Biologika is listed as an emerging player.
Does Intervacc have an API?
No public API is recorded for Intervacc.
What industry is Intervacc in?
Intervacc's product category is Animal Health Vaccines. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA). Its NAICS code is 325414 and its SIC code is 2836.